126
Management
Table 29. Medical Cancer Therapy Associated With Increased
Risk of AF (>1%)
Cancer Therapy
Frequency Reported
in Clinical Trials and
Observational Studies Comments
Common:
Incidence
1%–10%
Frequent:
>10%
Anthracyclines
Doxorubicin,
epirubicin, idarubicin,
mitoxantrone
×
AF may be a secondary result
of anthracycline cardiotoxicity;
studies in different populations
demonstrate variable risk of AF
Antimetabolites
Clofarabine combined
with cytarabine
× ×
×
5 fluorouracil (5FU)
×
Cepecitabine
Gemcitabine
Alkylating agents
Cyclophosphamide
Melphalan + stem cell
transplantation
× ×*
* Stem cell transplantation is
associated with an increased
risk of AF, and the risk may
be higher with melphalan-
associated regimens
Immunomodulatory
drugs
×
Given rates reported from
patients with multiple
myeloma, AF due to
underlying cardiac AL amyloid
may contribute
Lenalidomide
×
Interleukin-2
